See more : Critical Metals Corp. (CRML) Income Statement Analysis – Financial Results
Complete financial analysis of OptiNose, Inc. (OPTN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OptiNose, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Aekyungchemical Co., Ltd. (161000.KS) Income Statement Analysis – Financial Results
- A.G. BARR p.l.c. (BAG.L) Income Statement Analysis – Financial Results
- Gol Linhas Aéreas Inteligentes S.A. (GOLLQ) Income Statement Analysis – Financial Results
- AvalonBay Communities, Inc. (0HJO.L) Income Statement Analysis – Financial Results
- San Lorenzo Gold Corp. (SNLGF) Income Statement Analysis – Financial Results
OptiNose, Inc. (OPTN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.optinose.com
About OptiNose, Inc.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.99M | 76.28M | 74.65M | 49.12M | 34.63M | 7.07M | 0.00 | 47.50M | 85.00K |
| Cost of Revenue | 8.63M | 9.26M | 9.15M | 7.52M | 5.29M | 1.59M | 164.00K | 0.00 | 0.00 |
| Gross Profit | 62.35M | 67.01M | 65.50M | 41.60M | 29.34M | 5.48M | -164.00K | 47.50M | 85.00K |
| Gross Profit Ratio | 87.84% | 87.86% | 87.74% | 84.69% | 84.71% | 77.52% | 0.00% | 100.00% | 100.00% |
| Research & Development | 5.30M | 15.26M | 25.32M | 23.38M | 20.78M | 10.10M | 16.83M | 15.31M | 22.16M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 95.62M | 31.70M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 79.80M | 107.65M | 106.63M | 105.44M | 104.16M | 95.62M | 31.70M | 6.87M | 6.01M |
| Other Expenses | 0.00 | -18.94M | -15.85M | -12.57M | -14.45M | -6.42M | -372.00K | 0.00 | 0.00 |
| Operating Expenses | 85.10M | 122.91M | 131.95M | 128.82M | 124.94M | 105.72M | 48.53M | 21.45M | 27.52M |
| Cost & Expenses | 93.74M | 132.17M | 141.10M | 136.34M | 130.23M | 107.31M | 48.53M | 21.45M | 27.52M |
| Interest Income | 2.53M | 513.00K | 52.00K | 426.00K | 2.36M | 2.45M | 303.00K | 143.00K | 28.00K |
| Interest Expense | 19.53M | 16.84M | 15.97M | 13.01M | 9.62M | 9.23M | 910.00K | 3.52M | 819.00K |
| Depreciation & Amortization | 402.00K | 532.00K | 645.00K | 1.45M | 1.11M | 535.00K | 164.00K | 83.00K | 75.00K |
| EBITDA | -15.55M | -57.46M | -65.68M | -85.32M | -99.32M | -96.89M | -48.36M | 25.40M | -27.42M |
| EBITDA Ratio | -21.91% | -73.28% | -89.01% | -177.57% | -276.06% | -1,418.83% | 0.00% | 55.31% | -32,154.12% |
| Operating Income | -22.75M | -55.90M | -66.45M | -87.22M | -95.60M | -100.24M | -48.53M | 25.32M | -28.08M |
| Operating Income Ratio | -32.05% | -73.28% | -89.01% | -177.57% | -276.06% | -1,418.83% | 0.00% | 53.31% | -33,031.76% |
| Total Other Income/Expenses | -12.74M | -18.94M | -15.85M | -12.57M | -14.45M | -6.42M | -372.00K | -2.71M | -237.00K |
| Income Before Tax | -35.48M | -74.83M | -82.30M | -99.79M | -110.05M | -106.66M | -48.90M | 22.61M | -28.31M |
| Income Before Tax Ratio | -49.99% | -98.11% | -110.24% | -203.16% | -317.79% | -1,509.67% | 0.00% | 47.61% | -33,310.59% |
| Income Tax Expense | 0.00 | 1.56M | -646.00K | -1.46M | -1.11M | 2.81M | -164.00K | 3.52M | 819.00K |
| Net Income | -35.48M | -76.40M | -81.65M | -98.33M | -108.95M | -106.66M | -48.90M | 22.61M | -28.31M |
| Net Income Ratio | -49.99% | -100.16% | -109.37% | -200.20% | -314.59% | -1,509.67% | 0.00% | 47.61% | -33,310.59% |
| EPS | -0.32 | -0.89 | -1.44 | -2.04 | -2.60 | -2.68 | -4.45 | 0.36 | -1.06 |
| EPS Diluted | -0.32 | -0.89 | -1.44 | -2.04 | -2.60 | -2.68 | -4.45 | 0.06 | -1.06 |
| Weighted Avg Shares Out | 112.08M | 85.90M | 56.85M | 48.28M | 41.88M | 39.77M | 11.00M | 26.72M | 26.72M |
| Weighted Avg Shares Out (Dil) | 112.08M | 85.90M | 56.85M | 48.28M | 41.88M | 39.77M | 11.00M | 26.72M | 26.72M |
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript
OptiNose (OPTN) Reports Break-Even Earnings for Q3
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Optinose Appoints Terry Kohler as Chief Financial Officer
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports